Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.
Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL).
Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, may help reduce the symptoms of atopic dermatitis, according to the results of two randomized, double-blind, placebo-controlled, phase III trials.
Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.
Ipilimumab, given as adjuvant therapy after complete resection of stage III melanoma, significantly improved overall survival (OS) and distant metastases-free survival (DMFS) vs placebo, according to new results from the EORTC 18071 trial. [ESMO 2016, abstract LBA2_PR]